Okayama University Hospital was selected as a Cancer Genome Medicine Core Hospital, which are hospitals that play a central role in cancer and genomic medicine, where the genetic information of a cancer patient is used to choose the optimal drug and therapy for the patient. On February 14, 2018, an investigation committee of the Ministry of Health, Labour and Welfare selected the hospital to implement cancer and genomic medicine nationwide, and the hospital began to serve as a Cancer Genome Medicine Core Hospital in April 2018 under the designation of the Minister of Health, Labour and Welfare.

A Cancer Genome Medicine Core Hospital is a key medical institution that conducts genetic testing for cancer and various other diseases and selects appropriate therapies, and is also involved in research and new drug development and in developing human resources working in the field of cancer and genomic medicine. Applications for designation as a Cancer Genome Medicine Core Hospital were submitted by 23 hospitals from across the country, and 11 hospitals, including Okayama University Hospital, were selected.